Antiretroviral therapy in Africa
- PMID: 14751902
- PMCID: PMC324462
- DOI: 10.1136/bmj.328.7434.280
Antiretroviral therapy in Africa
Abstract
We should stop and think about the risks of resistance, and ways of minimising them, before increasing access to antiretroviral therapy in Africa
Figures
References
-
- Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243: 1731-4. - PubMed
-
- Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News 2000;6: 65-91
-
- Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998;3: 215-30. - PubMed
-
- Quinones-Mateu ME, Arts EJ. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Update 2002;5: 224-33. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources